M. Mabro

发表

Surgical treatment of rectal cancer: results of a strategy for selective preoperative radiotherapy.

J. Dubrez, P. Aegerter, M. Bernier, 2007, Gastroenterologie clinique et biologique.

Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial.

W. Scheithauer, F. Bonnetain, A. de Gramont, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An EGFR Pathway-Oriented Pharmacogenetic Study in MetastaticColorectal Cancer Patients Receiving Panitumumab and Irinotecan

C. Tournigand, P. Laurent-Puig, H. Blons, 2016 .

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.

G. Milano, L. Mineur, M. Etienne-Grimaldi, 2010, British journal of clinical pharmacology.

Bimonthly Leucovorin, Infusion 5-Fluorouracil, Hydroxyurea, and Irinotecan (FOLFIRI-2) for Pretreated Metastatic Colorectal Cancer

A. de Gramont, T. André, C. Louvet, 2003, American journal of clinical oncology.

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

M. Ychou, G. Deplanque, Y. Bécouarn, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.

C. Tournigand, A. Figer, F. Bidard, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients

A. de Gramont, B. Landi, T. André, 2006, British Journal of Cancer.

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly

J. Ezenfis, I. Etienney, T. Aparicio, 2003, British Journal of Cancer.

A Risk-Benefit Assessment of Amifostine in Cytoprotection

E. Raymond, S. Faivre, M. Mabro, 1999, Drug safety.

Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.

C. Tournigand, F. Bidard, M. Hebbar, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.

C. Tournigand, A. de Gramont, T. André, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors of Colorectal Cancer patients with Brain Metastases.

A. Lièvre, D. Tougeron, J. Bennouna, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

L'aspirine contre le cancer

A. D. Gramont, M. Mabro, 2000 .

OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study.

L. Mineur, A. de Gramont, A. Gramont, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial

P. Laurent-Puig, O. Bouché, T. Mazard, 2021, Clinical Cancer Research.

From a voluntary vaccination policy to mandatory vaccination against COVID-19 in cancer patients: an empirical and interdisciplinary study in bioethics

C. Hervé, P. Beuzeboc, Henri-Corto Stoeklé, 2022, BMC medical ethics.

[Primary hyperparathyroidism associated with colon cancer].

C. Tournigand, E. Lucchi, A. de Gramont, 2001, Gastroenterologie clinique et biologique.

Antitumour activity of pemetrexed (Pem) and irinotecan (Iri) in second-line metastatic colorectal cancer (MCRC) patients: A multicenter phase II study

M. Hebbar, E. Gamelin, A. Gramont, 2007 .

Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.

C. Tournigand, P. Laurent-Puig, F. Penault-Llorca, 2013 .

497OBEVACIZUMAB-ERLOTINIB AS MAINTENANCE THERAPY IN METASTATIC COLORECTAL CANCER. FINAL RESULTS OF THE GERCOR DREAM STUDY.

C. Tournigand, W. Scheithauer, F. Bonnetain, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II evaluation of an alternated FOLFOX/FOLFIRI regimen in patients with resistant metastatic colorectal cancer (CRC)

C. Tournigand, M. Hebbar, A. Gramont, 2001 .

[Bimonthly 5-fluorouracil in elderly patients with metastatic colorectal cancer. Study of 50 patients].

A. de Gramont, C. Louvet, M. Krulik, 1999, La Revue de medecine interne.

473OThree versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results

M. Ychou, G. Deplanque, Y. Bécouarn, 2017 .

[Oral granisetron solution as prophylaxis for chemotherapy-induced emesis in children: double-blind study of 2 doses].

R. Cohn, E. Madon, G. Margueritte, 2000, Bulletin du cancer.

CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.

J. Lotz, A. de Gramont, A. Gramont, 1999, European journal of cancer.

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration

P. Laurent-Puig, M. Ychou, G. Deplanque, 2019, Annals of Oncology.

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.

C. Tournigand, W. Scheithauer, D. Vernerey, 2015, The Lancet. Oncology.

C. Tournigand, P. Laurent-Puig, F. Penault-Llorca, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study

F. Pruvot, M. Hebbar, F. Bonnetain, 2013, Journal of chemotherapy.

Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer.

C. Tournigand, J. Taïeb, A. de Gramont, 2002, European journal of cancer.

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.

C. Tournigand, L. Mineur, A. Larsen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study

C. Hervé, P. Beuzeboc, Henri-Corto Stoeklé, 2021, European Journal of Cancer.

Adjuvant Therapy of Colorectal Cancer in Older People

A. Gramont, M. Mabro, E. Carola, 2013 .

Phase II Trial Alternating FOLFOX-6 and FOLFIRI Regimens in Second-Line Therapy of Patients with Metastatic Colorectal Cancer (FIREFOX Study)

C. Tournigand, M. Hebbar, A. de Gramont, 2006, Cancer investigation.

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

N. Magné, B. Chauffert, F. Ducray, 2020, European Journal of Cancer.

1204MO PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

K. Le Malicot, C. Louvet, D. Tougeron, 2022, Annals of Oncology.

Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study

G. Prager, R. Guimbaud, L. Mineur, 2023, Gastric Cancer.

Prognostic Factor Analysis in Advanced Gastric Cancer Patients Treated with Hydroxyurea, Leucovorin, 5-Fluorouracil, and Cisplatin (HLFP Regimen)

J. Vaillant, A. de Gramont, E. Gamelin, 2003, Cancer investigation.

Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).

C. Tournigand, J. Lotz, A. de Gramont, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study

O. Bouché, F. Bonnetain, J. Taieb, 2017, Oncotarget.

The prospective French participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients’ characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy.

Y. Bécouarn, O. Bouché, F. Bonnetain, 2016 .

Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer

M. Hebbar, A. de Gramont, E. Gamelin, 2010, Journal of oncology.

High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).

J. Lotz, A. de Gramont, A. Gramont, 2001, European journal of cancer.

Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2—Results of the induction phase of the GERCOR DREAM randomized phase III study.

C. Tournigand, W. Scheithauer, F. Bonnetain, 2015 .

Surgical treatment of rectal cancer: results of a strategy for selective preoperative radiotherapy.

J. Dubrez, P. Aegerter, P. Frileux, 2007, Gastroenterologie clinique et biologique.

Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19).

G. Piessen, O. Bouché, C. Eveno, 2019, Journal of Clinical Oncology.

Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.

C. Tournigand, F. Bidard, A. Gramont, 2009, Annals of Oncology.

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial.

F. Pruvot, M. Ychou, F. Bonnetain, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: Results of the GERCOR DREAM phase III trial.

C. Tournigand, W. Scheithauer, F. Bonnetain, 2013 .

M. Ychou, G. Deplanque, Y. Bécouarn, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.